Immunological biomarkers for the development and progression of type 1 diabetes
Immune biomarkers of type 1 diabetes are many and diverse. Some of these, such as the autoantibodies, are well established but not discriminative enough to deal with the heterogeneity inherent to type 1 diabetes progression. As an alternative, high hopes are placed on T cell assays, which give insight into the cells that actually target the beta cell or play a crucial role in maintaining tolerance. These assays are approaching a level of robustness that may allow for solid conclusions on both disease progression and therapeutic efficacy of immune interventions. In addition, ‘omics’ approaches to biomarker discovery are rapidly progressing. The potential emergence of novel biomarkers creates a need for the introduction of bioinformatics and ‘big data’ analysis systems for the integration of the multitude of biomarker data that will be available, to translate these data into clinical tools. It is worth noting that it is unlikely that the same markers will apply to all individuals. Instead, individualised signatures of biomarkers, combining autoantibodies, T cell profiles and other biomarkers, will need to be used to classify at-risk patients into various categories, thus enabling personalised prediction, prevention and treatment approaches. To achieve this goal, the standardisation of assays for biomarker discovery, the integration of analyses and data from biomarker studies and, most importantly, the careful clinical characterisation of individuals providing samples for these studies are critical. Longitudinal sample-collection initiatives, like INNODIA, should lead to novel biomarker discovery, not only providing a better understanding of type 1 diabetes onset and progression, but also yielding biomarkers of therapeutic efficacy of interventions to prevent or arrest type 1 diabetes.
KeywordsAutoantibodies Bioinformatics Biomarker Immune Review T cell assays Type 1 diabetes
Forkhead box P3
Glutamic acid decarboxylase
Immunology of Diabetes Society
Peripheral blood mononuclear cells
Effector T cells
Regulatory T cells
We thank C. Moyson (Department of Endocrinology, UZ Leuven, Leuven, Belgium) for editorial help.
All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.
Related work in the laboratories of all authors is funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2-JU) under grant agreement no. 115797 INNODIA. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, JDRF International and The Leona M. and Harry B. Helmsley Charitable Trust.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
- 10.Lampasona V, Liberati D (2016) Islet autoantibodies. Curr Diab Rep 16:53. https://doi.org/10.1007/s11892-016-0738-2
- 24.Tree TI, Lawson J, Edwards H et al (2010) Naturally arising human CD4 T cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T cell responses via linked suppression. Diabetes 59:1451–1460. https://doi.org/10.2337/db09-0503 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Alhadj Ali M, Liu YF, Arif S et al (2017) Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med 9:eaaf7779. https://doi.org/10.1126/scitranslmed.aaf7779
- 28.Heninger AK, Eugster A, Kuehn D et al (2017) A divergent population of autoantigen-responsive CD4+ T cells in infants prior to beta cell autoimmunity. Sci Transl Med 9:eaaf8848. https://doi.org/10.1126/scitranslmed.aaf8848
- 32.Orban T, Beam CA, Xu P et al (2014) Reduction in CD4 central memory T cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 63:3449–3457. https://doi.org/10.2337/db14-0047 CrossRefPubMedPubMedCentralGoogle Scholar